 ROCKVILLE, Md., June 28, 2021 PRNewswire -- RegeneRx Biopharmaceuticals, Inc. OTCQB: RGRX RegeneRx, a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that it has entered into a definitive agreement with certain institutional and accredited investors, including certain directors and officers of the Company, in connection with a private placement of up to 2,000,000 of shares of its common stock and warrants at a purchase price of 0.20 per share and accompanying warrants. 